Sorrento Therapeutics Inc. (SRNE): Price and Financial Metrics

Sorrento Therapeutics Inc. (SRNE): $0.01

0.00 (-9.09%)

POWR Rating

Component Grades

Momentum

D

Stability

D

Sentiment

Quality

C

Add SRNE to Watchlist
Sign Up

Industry: Biotech

Industry

NR

Ranked

#200 of 400

in industry

SRNE Price/Volume Stats

Current price $0.01 52-week high $0.42
Prev. close $0.01 52-week low $0.00
Day low $0.01 Volume 377,050
Day high $0.02 Avg. volume 359,840
50-day MA $0.01 Dividend yield N/A
200-day MA $0.05 Market Cap 5.51M

SRNE Stock Price Chart Interactive Chart >


Sorrento Therapeutics Inc. (SRNE) Company Bio


Sorrento Therapeutics, Inc. engages in the research, development and manufacture of biopharmaceutical products. It focuses on therapies to treat specific stages in the evolution of cancer, from elimination, to equilibrium and escape which include biosimilars, immuno-oncology antibodies, cellular therapy, cell internalizing antibodies, and antibody drug conjugates. The company was founded by Henry H. Ji in 2006 and is headquartered in San Diego, CA.


SRNE Latest News Stream


Event/Time News Detail
Loading, please wait...

SRNE Latest Social Stream


Loading social stream, please wait...

View Full SRNE Social Stream

Latest SRNE News From Around the Web

Below are the latest news stories about SORRENTO THERAPEUTICS INC that investors may wish to consider to help them evaluate SRNE as an investment opportunity.

Scilex Holding Company announces the commercial launch of ELYXYBTM (celecoxib oral solution) in the U.S., strengthening its leadership position in non-opioid pain management

ELYXYBTM is a first-line treatment and the only FDA-approved, ready-to-use oral solution for the acute treatment of migraine, with or without aura, in adults.1 The U.S. oral migraine drug market size is estimated to be $1.8 billion in 2022.2There is strong evidence for the use of NSAIDs as a first-line treatment for migraine. Celecoxib is in the same class of agents, is fast acting, and has the potential to have the lowest GI side effects of all NSAIDs.3Strong re-launch commercialization efforts

Yahoo | February 27, 2023

The $75 Million Reason Sorrento (SRNE) Stock Is Moving Today

SRNE stock is moving this morning after soaring about 25% yesterday.

Larry Ramer on InvestorPlace | February 22, 2023

Alphabet Layoffs 2023: What to Know About the Latest Google Job Cuts

Alphabet (GOOGL,GOOG) layoffs are worth checking on Wednesday as recent reports claim Google job cuts are coming to Ireland.

William White on InvestorPlace | February 22, 2023

Meta Platforms Layoffs 2023: Are More Facebook Job Cuts Coming?

Meta Platforms (META) layoffs are a hot topic on Wednesday as reports spread that the Facebook parent company is planning more job cuts.

William White on InvestorPlace | February 22, 2023

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

We're starting off the day with a breakdown of the biggest pre-market stock movers traders need to watch on Wednesday morning!

William White on InvestorPlace | February 22, 2023

Read More 'SRNE' Stories Here

SRNE Price Returns

1-mo -4.76%
3-mo 25.00%
6-mo -91.48%
1-year -97.13%
3-year -99.90%
5-year -99.71%
YTD -91.90%
2023 -86.06%
2022 -80.95%
2021 -31.87%
2020 101.92%
2019 40.83%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!